Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 3:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,050 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine, Bevacizumab
Drug · Biological
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
8
States / cities
Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 5 more
Conditions
Polycystic Ovary Syndrome, Insulin Resistance
Interventions
walnuts, almonds
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Mather, California
Conditions
Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Multiple Myeloma, Lymphoma
Interventions
Carfilzomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
7
States / cities
Scottsdale, Arizona • Beverly Hills, California • Chicago, Illinois + 4 more
Conditions
Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Interventions
BL-M07D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 19 more
Conditions
Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx
Interventions
erlotinib hydrochloride, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
flow cytometry, immunohistochemistry staining method
Other
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Lymphoma, Nausea, Vomiting, Neuroblastoma, Ovarian Cancer, Sarcoma
Interventions
electroacupuncture therapy, sham intervention, quality-of-life assessment
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

The Experience of Living With Polycystic Ovary Syndrome in the Military

NCT03876665
Conditions
Polycystic Ovary Syndrome
Interventions
No intervention
Other
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Travis Air Force Base, California
Conditions
Ovarian Cancer
Interventions
Technology-based Mindful Living program, Technology-based Healthy Lifestyles program
Behavioral
Lead sponsor
Susan Lutgendorf
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Miami, Florida • Iowa City, Iowa • Omaha, Nebraska + 1 more
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

NCT04327934
Conditions
Polycystic Ovary Syndrome, Hypertension
Interventions
GnRH antagonist, GnRH antagonist + MethylTESTOSTERone 5 MG
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Recurrent Ovarian Cancer, Fallopian Tube Cancer
Interventions
Usual Care Educational Website, Prototype System
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Peritoneal Neoplasms
Interventions
nanoparticulate paclitaxel
Drug
Lead sponsor
CritiTech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Kansas City, Kansas • Wichita, Kansas • Oklahoma City, Oklahoma
Conditions
Stage II Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer, Stage II Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage II Cervical Cancer, Stage III Cervical Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Stage II Kidney Cancer, Stage III Kidney Cancer, Stage IV Kidney Cancer
Interventions
Behavioral Intervention
Behavioral
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 5 more
Completed Not applicable Interventional Accepts healthy volunteers

Time Restricted Eating for the Treatment of PCOS

NCT05629858
Conditions
Polycystic Ovary Syndrome, Obesity, Overweight
Interventions
6-h Time restricted eating (TRE), Calorie restriction (CR), Control
Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions
navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy
Biological
Lead sponsor
OncXerna Theraputics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 5 more
Conditions
Ovarian Cancer, Pancreatic Cancer
Interventions
DMUC5754A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
Conditions
Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
niraparib, pembrolizumab
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Conditions
Epithelial Ovarian Cancer
Interventions
Torvutatug samrotecan, Bevacizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
6
States / cities
Tamarac, Florida • Tampa, Florida • Baton Rouge, Louisiana + 3 more
Conditions
Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary
Interventions
Standard of Care + atorvastatin, Standard of Care (SOC)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Gynecologic Neoplasms, Epithelial Ovarian Cancer, Uterine Endometrial Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
AA Secord
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
Depot Lupron followed by estrogen plus placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
topotecan hydrochloride, adjuvant therapy
Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Houston, Texas
Conditions
Fallopian Tube Carcinoma, Ovarian Carcinoma
Interventions
Photoacoustic Imaging
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California